Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07430722 · ClinicalTrials.gov registry record
Cross-sectional Study of Vitamin B6 in Parkinson's Disease
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 288
- Enrollment target
NCT07430722: Completed study, sponsored by University of Rochester.
NCT07430722 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 288 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07430722 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 288 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the prevalence of abnormal serum levels of vitamin B6, and the associations of those levels with demographic and clinical variables in a randomly selected sample of people living with Parkinson's disease, compared to historical controls.
Primary Outcome
nmol/L (log-transformed)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2026-02-15 |
What the finished NCT07430722 record still lists
NCT07430722 is an observational study that tracks outcomes without assigning an intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07430722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07430722 about?
NCT07430722 is a clinical study titled "Cross-sectional Study of Vitamin B6 in Parkinson's Disease". The purpose of this study is to estimate the prevalence of abnormal serum levels of vitamin B6, and the associations of those levels with demographic and clinical variables in a randomly selected sample of people living with Parkinson's disease, compared to historical controls.
What is the current status of trial NCT07430722?
This trial is currently completed. The enrollment target is 288 participants. The study started on 2024-07-01. Estimated completion is 2026-02-15.
Who is sponsoring clinical trial NCT07430722?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI